VRB-101 for Obesity

Not yet recruiting at 16 trial locations
VB
Overseen ByVerdiva Bio Medical Affairs
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Verdiva Bio Dev Limited
Must be taking: Semaglutide, Tirzepatide
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.

Are You a Good Fit for This Trial?

Inclusion Criteria

I have used weekly semaglutide or tirzepatide injections for at least 6 months.
I have lost at least 10% of my body weight in the past 6 months and kept it off.
* Participants of childbearing potential (POCBP) must be non-pregnant and non-lactating and must agree to use study-specified contraceptive methods.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

Treatment

Participants receive weekly oral doses of VRB-101 or placebo for weight maintenance

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Ecnoglutide (VRB-101)

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Placebo Group

Group I: VRB-101 (Active Arm 3)Experimental Treatment1 Intervention
Group II: VRB-101 (Active Arm 2)Experimental Treatment1 Intervention
Group III: VRB-101 (Active Arm 1)Experimental Treatment1 Intervention
Group IV: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Verdiva Bio Dev Limited

Lead Sponsor